FIRST-LINE MAINTENANCE THERAPY OF ADVANCED OVARIAN CANCER WITH ZEJULA (niraparib)
Dosing Information From the PRIMA Trial
Respond with ZEJULA, a convenient
once-daily maintenance treatment1
Once-Daily
Oral Monotherapy

Taken With
or Without Food

Taken Any Time
of the Day

ZEJULA should be taken at approximately the same time each day1
Drug-Drug
Interactions

No specific drug-drug interactions have been reported with ZEJULA*
*No clinical drug interaction studies have been performed with ZEJULA.
The only once-daily PARP inhibitor with an individualized starting dose in 1L maintenance1-4
Starting Dose for 1L Maintenance Is Based on Baseline Weight and Platelet Count1


For patients with moderate hepatic impairment, reduce the starting dosage of ZEJULA to 200 mg once daily. Monitor patients for hematologic toxicity and reduce the dose further, if needed.1
Lower rates of select hematologic adverse reactions and similar efficacy were observed with an individualized starting dose1,5,6†
PRIMA prospectively evaluated the safety and efficacy of an individualized starting dose of either 200 mg or 300 mg, selected based on baseline weight and platelet count, as well as a fixed starting dose of 300 mg1†
Rates of Select Grade 3-4 Hematologic Adverse Reactions1,5


In PRIMA, patients in the overall and individualized populations experienced the same rates of Grades 3-4 leukopenia.1
The individualized starting dose was shown to be effective in
exploratory subgroup analyses† and is the approved starting dose
for ZEJULA in first-line maintenance1
HR, 0.68 (95% CI, 0.48-0.97) in the overall population (n=258)
HR, 0.39 (95% CI, 0.22-0.72) in the HRd population (n=130)
In the BRCAm population (n=53)6†
HR, 0.29 (95% CI, 0.128-0.667)
These analyses are exploratory in nature, do not control for type 1 error, and are not powered to determine treatment effect in any subgroup.
Continue the PRIMA story